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Abstract
Background: HCV transmission remains high in people who inject drugs (PWID) in Montréal. New direct-acting
antivirals (DAAs), highly effective and more tolerable than previous regimens, make a “Treatment as Prevention”
(TasP) strategy more feasible. This study assesses how improvements in the cascade of care could impact hepatitis
C burden among PWID in Montréal.
Methods: We used a dynamic model to simulate HCV incidence and prevalence after 10 years, and cirrhosis
complications after 10 and 40 years. Eight scenarios of improved cascade of care were examined.
Results: Using a baseline incidence and prevalence of 22.1/100 person-years (PY) and 53.1%, implementing the
current cascade of care using DAAs would lead to HCV incidence and prevalence estimates at 10 years of 9.4/100PY
and 55.8%, respectively. Increasing the treatment initiation rate from 5%/year initially to 20%/year resulted in large
decreases in incidence (6.4/100PY), prevalence (36.6%), and cirrhosis complications (−18%/-37% after 10/40 years).
When restricting treatment to fibrosis level≥ F2 instead of F0 (reference scenario), such decreases in HCV occurrence
were unreachable. Improving the whole cascade of care led to the greatest effect by halving both the incidence and
prevalence at 10 years, and the number of cirrhosis complications after 40 years.
Conclusions: The current level of treatment access in Montréal is limiting a massive decrease in hepatitis C burden among
PWID. A substantial treatment scale-up, regardless of fibrosis level, is necessary. While improving the rest of the cascade of
care is necessary to optimize a TasP strategy and control the HCV epidemic, a treatment scale-up is first needed.
Keywords: Dynamic model, HCV elimination, Treatment initiation criteria, Cascade of care, Direct-acting antiviral, People
who inject drugs
Background
Drug injection is the main transmission route for hepa-
titis C virus (HCV) in high income countries [1]. The
number of active people who inject drugs (PWID) (de-
fined as injecting in the past six months) in Montréal is
estimated to be 4,000 [2]. According to regional
surveillance data (SurvUDI network), approximately 70%
of this population has been exposed (antibody positive)
to HCV [3] and the number of new infections remains
high: 22.1/100 persons-years (PY) for the 2010–2013
period (unpublished SurvUDI data).
Access to HCV treatment remains limited in this
population. Several components of the HCV cascade of
care may explain poor treatment uptake. During 2003–
2011, 23% of the infected PWID reported they were not
aware of their infection; among those who were aware,
45% reported a physician consultation in the past
6 months, and 12% initiated HCV treatment [3]. There
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may be reluctance on the part of physicians to initiate
antiviral treatment in PWID [4]. Precarious living condi-
tions and other co-morbidities (e.g., psychiatric disor-
ders) may have been identified as barriers to treatment
initiation [5]. Also, uncontrolled substance use often
constitutes a treatment barrier and many physicians
prefer to treat PWID who participate in opiate substitu-
tion programs [4]. Until recently, the standard antiviral
treatment regimen for HCV (dual therapy pegylated
interferon plus ribavirin) implied numerous challenges.
The regimen required a treatment duration of 24 to
48 weeks and the sustained virological response (SVR)
rate was only 45% for genotype 1, [6, 7], the most
common genotype in Montréal [8]. Moreover, this
treatment regimen required weekly injections of
peginterferon, and was associated with severe adverse
events such as rash, anemia and/or depression [6, 7].
The current HCV cascade of care is largely reflective
of the period where these treatments represented the
only option to cure HCV.
However, since 2014 direct-acting antiviral (DAA)
molecules for HCV treatment are increasingly avail-
able. These treatments are more effective (>90% SVR
for all genotypes), shorter (12 weeks), less restrictive
as oral regimens, and they cause few or no adverse
events [9–14]. These recent advance in the HCV
therapeutic area provides an interesting opportunity
for the elimination of HCV infection in this popula-
tion, defined as the ‘reduction to zero of the incidence
of infection [15, 16]. The successful treatment of
infected individuals could limit the transmission of the
virus to current or future injecting partners and pre-
vent the occurrence of serious health outcomes such
as end-stage liver disease. However, if a “Treatment as
Prevention” (TasP) strategy is to work, it will require
enhancements in the “HCV cascade of care”, including
increased HCV testing, linkage to HCV care, improved
liver fibrosis assessment, greater HCV treatment up-
take, and improved adherence and cure of HCV [17].
In this paper, we used a previously developed dynamic
stochastic model for HCV transmission in PWID [18] to
estimate the impact of a TasP strategy on HCV transmis-
sion and related morbidity when varying the components
of the HCV cascade of care among PWID in Montréal.
Methods
Dynamic modeling was used to simulate HCV transmis-
sion and natural history. Details about the model and
related parameters are provided below and elsewhere [18].
Model
A previously described model of HCV transmission was
used to estimate the impact of a TasP strategy [18]. Briefly,
it is a stochastic individual-based model including the so-
cial network of PWID (i.e., people who inject together), to
take into account the background risk of HCV infection
between injecting partners [19] (see Additional file 1: S1).
Figure 1 describes the transition chart of the model for
HCV transmission and care. Figure 2 presents the natural
history of HCV infection; two complications can occur in
cirrhosis: decompensation and hepatocellular carcinoma
(HCC), which can lead to death. The infection rate for an
Fig. 1 Transition chart of the model for HCV infection and care. New PWID enters the population as “Susceptible (high risk)” – corresponding to
recent initiation of injection – for all the simulation period; this assures a constant population size (i.e. each death in the population implies the
arrival of a new PWID). Plain arrows correspond to transitions occurring according to exponential probability distributions. Dashed lines correspond to
transitions occurring after a fixed time with a given probability. Dotted lines correspond to transitions related to the natural history model. An
individual is considered as Detected if he/she has an HCV antibody positive test. An individual is considered as Linked to care if he/she had one or
more consultation related to his/her HCV infection in the past 6 months (with the first link to care corresponding to the first positive RNA test, see
Additional file 1: S2)
Cousien et al. BMC Infectious Diseases  (2017) 17:162 Page 2 of 10
individual depends on his/her social network, the latter
being modelled by a random graph which is assumed to
be static (with replacement of dead PWID by new individ-
uals in the network). Finally, the model includes rates of
permanent or sustained injection cessation (i.e., relapse is
not considered in the model) and general mortality (i.e.,
non-HCV-related mortality) which also depends on the
injecting status (active or inactive, i.e. after cessation of in-
jection) of PWID overtime.
The starting population is Montréal’s active PWID
population (i.e., people who injected in the past
6 months), estimated to be 4,000 individuals [2]. Due to
limited data regarding the evolution of the population
size of PWID in Montréal, the population size is
assumed constant in time: each dead PWID is replaced
in the model by another non-infected PWID.
Parameters
Key parameters are presented in Table 1. Where possible
we used regional data reflecting the local context. Sur-
vUDI, a bio-behavioural surveillance system for HCV
and HIV infections among PWID in Eastern Central
Canada and targeting hard-to-reach PWID, provided
most of the estimates for model parameters. Eligibility
criteria included age 14 years and older, injecting at least
once within the past six months, and speaking French or
English [3]. Particularly, the contact rate β was fitted by
Approximate Bayesian Computation (or ABC) to repro-
duce, during the first year of simulation, the incidence
observed in Montreal for active PWID participating in
SurvUDI for the 2010–2013 period, i.e. 22/100PY. ABC
is a bayesian method used to infer some parameters of a
model without likelihood estimation [20]. Details about
the method are provided in Additional file 1: S2. Other
parameters were derived from the scientific literature.
Additional file 1: S2 provides details and underlying
assumptions for the model.
Outcomes
The outcomes of interest were: occurrence of HCV
infection (average incidence and prevalence after 10y)
and related morbidity (average number of cirrhosis com-
plications avoided over 10 and 40y). This time horizon
for the number of cirrhosis complications was chosen
because of the long delay before the occurrence of
HCV-related complications. The outcomes were esti-
mated for whole PWID populations (active plus inactive
injectors) except incidence, for which only active PWID
are at risk of infection. For each outcome, we presented
a mean and the associated 95% confidence interval.
In addition, for each scenario, the mean numbers of
treatments initiated (and completed unless the individual
dies during the treatment) over 40y were estimated.
Scenarios
Using 8 different scenarios (see Table 2), we estimated
the impact of improvements in the HCV cascade of care
on HCV occurrence and morbidity in the Montréal
PWID population. One thousand epidemic trajectories
were simulated to derive the effects of each of the eight
following scenarios:
S1 (reference): The recommended HCV cascade of
care among PWID using Sofosbuvir (for all stages of
liver fibrosis), which corresponds to the situation at the
time the study was done. Mean time from the end of
acute hepatitis C to detection: 2y; mean time from
detection to linkage to care: 1.7y; annual loss to follow-
up rate: 10.2%/y; treatment initiation rate (when linked
to care): 5%/y; SVR rates: 81% (90% for Sofosbuvir based
regimens in clinical trials multiplied by a coefficient of
0.9 to account for the difference between real-world and
clinical trial contexts, see Additional file 1: S2); duration
of the treatment: 12 weeks.
In this reference scenario, treatment initiation can
occur for fibrosis scores ≤ F4. Indeed, the initiation of
HCV treatment among PWID should be individualized
as recommended by several professional societies and
expert panels (Canadian Association for the Study of the
Liver [21] and the American Association for the Study
of the Liver [22]), and current recommendations regarding
the use of Sofosbuvir in Québec do not include severe fi-
brosis scores as a requirement for reimbursement ([23],
Québec Institute for Excellence in Health and Social Ser-
vices (INESSS) [24]). Such restrictions exist, however, for
more recent combined DAA regimens [23].
Fig. 2 Transition chart for the natural history of chronic hepatitis C. All transitions occur according to exponential probability distributions. Fibrosis
progression is quantified using Metavir Score [42]: F0 = No fibrosis, F1 = Portal fibrosis without septa, F2 = portal fibrosis with few septa, F3 = numerous
septa without cirrhosis, F4 = cirrhosis. Metavir fibrosis scores F0 and F1 (respectively F2 and F3) were gathered in a F0/1 (respectively F2/3) state
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S2: S1 with an improvement in the mean time to
detection of chronic HCV from 2y to 0.5y (1y after the
infection, due to the 6 months of acute hepatitis C in
the model), and corresponding to annual testing, as
supported by AASLD guidelines [22].
S3: S1 with an improvement in linkage to care, with a
mean time to linkage to care from 1.7y to 0.5y and a loss
to follow-up rate from 10.2%/y to 5%/y.
S4: S1 with an improvement in adherence to treat-
ment. In this scenario, we improved the SVR rate of 81%
to the level demonstrated in clinical trials, i.e. 90%.
S5: S1 with an improvement in treatment initiation
rate from 5%/y to 10%/y when linked to care.
S6: Improvement in treatment initiation rate from 5%/
y to 20%/y when linked to care.
S7: Combined scenarios S2, S3, S4 and S6 to determine
the impact of improvements in the entire cascade of care.
S8: S7 with an initiation of HCV treatment at fibrosis
levels F2-F3-F4 only. Due to the high cost of the new
DAAs (55,000$CAD [25]), there may be a reluctance to
treat people with minimal fibrosis (F0/F1 fibrosis scores)
[22]. Therefore, simulations were performed based on
treatment initiation at fibrosis scores between F2 and F4,
i.e., 100% of the PWID with moderate or severe fibrosis
were treated (vs. 5% of all PWID in S1) while those with
F0 and F1 were excluded from treatment. The purpose
of this scenario is to assess the optimal outcomes that
could be obtained when restricting treatment to more
advanced fibrosis in a context where all PWID eligible
for treatment are treated.
Table 1 Key parameters of the model
Parameter Value References
Population size 4,000 [2]
Average number of injecting partners during the injecting career 12 Derived from [38]
Initial distribution (HCV infection and cascade of care)
Susceptible with high risk (recent initiation of injection) 10.10% SurvUDI, 2012–2014, unpublished data
Susceptible with low risk (experienced PWID) 36.80%
Acute hepatitis C 0%a
Non-detected chronic hepatitis C 8.40% SurvUDI, 2012–2014, unpublished data
Detected, non-linked to care chronic hepatitis C 24.40%
Detected and linked to care chronic hepatitis C 15.30%
Under treatment 0.40%
Non-responders after treatment 4.60%
Initial distribution in the natural history model





Infection rate by injecting partner in Susceptible (low risk) 0.025 y−1partner−1 Fitted by Approximate Bayesian Computation (ABC) to have
a 22.1/100 p-y baseline incidence (SurvUDI, 2010–2013)
Mean time from the end of acute hepatitis C to detection 2.0y Derived from SurvUDI, 2012–2014, unpublished data
Mean duration of the high-risk period, i.e. Susceptibles
(high risk, recently initiated PWID)
4.0y [39]
Mean time before linkage to care 1.7y Derived from Notifiable Disease Reporting System of the
Montréal Public Health Department
Loss to follow-up rate 10.3%/y Derived from SurvUDI, 2012–2014, unpublished data
Treatment initiation rate when linked to care 5%/y Approximate value derived from SurvUDI, 2012–2014,
based on current number of people under treatment (0.4%)
Treatment: incoming DAAs regimens
Duration 12 weeks [9–14]
SVR rate – treatment naive - all genotypes- clinical trials 90%
Mean duration of injecting career 9.5y [43]
PWID people who inject drugs; SVR: sustained virological response
aHypothesis
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Sensitivity analysis
The confidence intervals presented in the main analysis
only reflect the uncertainty due to the stochastic processes
of the model and not that associated with uncertainty in
parameter estimates (see Additional file 1: S6). To assess
the impact of the latter on our results, we performed
several sensitivity analyses.
First, we performed a deterministic univariate sensitiv-
ity analysis by varying the parameter values based on the
uncertainty interval (e.g., 95% confidence interval) if
available, or by using values from other studies. We var-
ied the following parameters in the model: infection rate,
mean duration of the high-risk period, relative risk of re-
infection after SVR, time between chronic infection and
detection, average time before linkage to care and loss to
follow-up rate, mortality rates, average duration of
injecting career and all the transitions rates in the nat-
ural history model (see Additional file 1: S5). Due to the
uncertainty about the number of injecting partners, we
also varied this parameter to cover the range of likely
values in the literature (between 3 and 15) [18]. More-
over, we did a sensitivity analysis where the spontaneous
recovery rate was set at 41% vs. 26%, as in the main ana-
lysis, because some studies suggest a higher recovery
rate among PWID compared with the general popula-
tion [26, 27]. Finally, we undertook an analysis using a
high-risk period of 1 year (instead of 4 years as done in
the main analysis) [28]. The details of theses analyses are
provided in Additional file 1: S5.
Results
Figure 3 presents boxplots representing the prevalence
and incidence distributions after 10y, and the proportion
of cirrhosis complications avoided over 10 and 40y, for
each scenario compared with S1, the reference. In
addition, the reader can refer to Additional file 1: S3, S4
and S7 for information on the evolution of outcomes
over time, the impact of each scenario on the disposition
of PWID in the cascade of care after 10 years, and the
number of infections and HCV-related deaths for each
scenario, respectively.
HCV transmission in the population
In the reference scenario S1, the mean incidence and
prevalence estimates after 10y were 9.4/100PY [95%
confidence interval: 9.2; 9.7] and 55.8% [55.6; 55.9],
respectively. Improved testing in S2, linkage to care in
S3 or adherence to treatment in S4, each taken separ-
ately, led to similar incidence estimates of 9.3/100PY
[9.1; 9.6], 9.1/100PY [8.8; 9.3] and 9.2/100PY [9.0; 9.5],
respectively. S2, S3 and S4 also led to similar prevalence
estimates: 54.7% [54.6; 54.9], 53.2% [53.1; 53.4] and
54.5% [54.4; 54.7]. Improvements in the treatment initi-
ation rate, from 10%/y to 20%/y in S5 and S6 led to a de-
crease in HCV occurrence with incidence estimates of
8.1/100PY [7.9; 8.3] and 6.4/100PY [6.2; 6.6], respect-
ively. Similarly, prevalence estimates decreased for S5
and S6: 47.5% [47.3; 47.6] and 36.6% [36.4; 36.7]. The
combined scenario S7 (representing improvements in
the whole cascade of care) was the most effective with the
incidence dropping to 4.3/100PY [4.2; 4.4] and prevalence
to 24.0% [23.9; 24.2] after 10y. Finally, when restricting
treatment to F2-F4 fibrosis scores in S8, the incidence and
prevalence estimates were 7.3/100PY [7.1; 7.5] and 44.3%
[44.1; 44.5], respectively.
Chronic hepatitis C complications
Compared with the reference scenario S1, improved test-
ing in S2, had almost no impact resulting in 0% [−1; 2]
and 1% [0; 3] of cirrhosis complications avoided over 10
and 40y, respectively. Improved linkage to care in S3,
and adherence to treatment in S4, had moderate effects
in the long term, with 2% [1; 4] and 1% [−1; 3] of com-
plications avoided after 10y and 6% [5; 7] and 6% [5; 7]
after 40y. Improvements in the treatment initiation rate
from 10%/y in S5 and to 20%/y in S6, resulted in the
avoidance of 7% [6; 9] and 18% [17; 20] of complications
after 10y, respectively, while greater decreases were
observed after 40y: 21% [20; 22] and 37% [36; 38]. The
Table 2 Description of the 8 scenarios simulated




Loss to follow-up rate (%/y) Treatment eligibility Treatment rate among
eligible PWID
%SVR
1 (reference) 2 y 1.7 y 10.2%/y F0→ F4 5%/y 81%
2 0.5 y 1.7 y 10.2%/y F0→ F4 5%/y 81%
3 2 y 0.5y 5%/y F0→ F4 5%/y 81%
4 2 y 1.7 y 10.2%/y F0→ F4 5%/y 90%
5 2 y 1.7 y 10.2%/y F0→ F4 10%/y 81%
6 2 y 1.7 y 10.2%/y F0→ F4 20%/y 81%
7 0.5 y 0.5 y 5%/y F0→ F4 20%/y 90%
8 0.5 y 0.5 y 5%/y F2→ F4 100%/y 90%
PWID People who inject drugs, SVR sustained virological response
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combined scenario S7 demonstrated a decrease of 30%
[29; 32] after 10y, and 54% [53; 54] after 40y, in the
number of cirrhosis complications. Finally, treating only
F2-F4 fibrosis levels in S8 led to a decrease of 44% [43; 45]
and 49% [48; 50] in complications after 10 and 40y,
respectively.
Sensitivity analysis
The tornado graphs in Additional file 1: S5 present vari-
ations in outcomes assuming the conditions of S1 while
considering parameter uncertainty levels. The parame-
ters determined to be most sensitive (top 10) in outcome
estimation are presented for each outcome. For the inci-
dence after 10 years, the most sensitive parameters were
the mean time to cessation of injection (with a variation
in the reference scenario S1 of −6.0/100 p.y, +3.9/100
p.y.), the treatment initiation rate (−1.3/100 p.y., 1.7/100
p.y.) and the infection rate per infectious injecting part-
ner (−1.6/100 p.y., 1.1/100 p.y.). The most sensitive
parameters for the prevalence after 10 years were the
treatment initiation rate (−8.3%, +8.7%) and the mean
time to cessation of injection (−9.0%, +5.1%). Finally, for
the number of cirrhosis complications within 10 years,
estimates were most sensitive to the transition rate from
F2/F3 to F4 (−18%, +22%), the fibrosis distribution in
the population (−28%, +0%) and the decompensation
rate (−10%, +15%). For cirrhosis complications after
40 years, estimates were most sensitive to the following
parameters: the treatment initiation rate (−21%, +37%),
the transition rate from F2/F3 to F4 (−29%, +26%) and
the transition rate from F0/F1 to F2/F3 (−15%; +11%).
In other sensitivity analyses, the trends of our results
remained unchanged when we varied the number of
injecting partners. In addition, we also simulated the 8
scenarios with the lower and upper bounds of the mean
time to cessation of injection used in the univariate
sensitivity analysis (4.7 years and 14 years), due to the
large impact on prevalence and incidence. The trends
observed for the various scenarios were relatively
unchanged.
Fig. 3 Results according to various HCV cascade of care scenarios; 1,000 simulations. a. Boxplots of the incidence at 10 years; b. Boxplots of the
prevalence at 10 years; c. Proportion of cirrhosis complications avoided after 10 years (mean percentage of new cirrhosis complications avoided,
compared with the reference scenario (S1)); d. Proportion of cirrhosis complications avoided after 40 years (mean percentage of new cirrhosis
complications avoided, compared with the reference scenario (S1)). S1 (reference): The current HCV cascade of care using the new DAAs. S2: S1
with an improvement in the mean time to detection of chronic HCV from 2y to 0.5y. S3: S1 with an improvement in linkage to care, with a decrease
in mean time to linkage to care from 1.7y to 0.5y and a loss to follow-up rate from 10.2%/y to 5%/y. S4: S1 with an improvement in adherence
to treatment, i.e. we improved the SVR rate of 81% to the level demonstrated in clinical trials, i.e. 90%. S5: S1 with an improvement in treatment initiation
rate from 5%/y to 10%/y when linked to care. S6: Improvement in the treatment initiation rate from 5%/y to 20%/y when linked to care. S7: Combined
scenarios S2, S3, S4 and S6 to determine the impact of improvements in the entire cascade of care; no fibrosis criteria for treatment initiation. S8: S1 with
an initiation of HCV treatment at fibrosis levels F2-F3-F4 only
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Discussion
We used an individual-based model to simulate the evolu-
tion of HCV infection among active PWID in Montréal
while varying the cascade of care. Model parameters were
primarily informed by local data. The results showed,
compared with the current cascade of HCV care, that the
best approach to curtail ongoing HCV transmission and
future cirrhosis complications in this population, is to
improve access to treatment. By increasing the treatment
initiation rate from 5%/y to 10%/y and 20%/y, prevalence
at 10y decreased from 55.8% to 47.5% and 36.6%, respect-
ively. Similarly, incidence rates at 10y dropped from 9.4/
100PY to 8.1/100PY and 6.4/100PY, respectively. In
addition, the number of cirrhosis complications decreased
by 21% and 37% over 40y using 10%/y and 20%/y treat-
ment initiation rates. Conversely, improved testing,
linkage to care or adherence to treatment alone, led to
minimal decreases in disease burden. However, combining
these improvements with a higher treatment initiation rate
permitted a decrease of almost 50% in the prevalence and
incidence at 10y and the number of cirrhosis complica-
tions over 40y. Finally, by restricting treatment to patients
with moderate and severe fibrosis (S8), the impact on
HCV transmission was considerably lower compared to
S7 (no fibrosis restriction, treatment initiation of 20%/y),
even in the optimistic case where 100% of the eligible indi-
viduals were treated. However, there was a greater impact
on the reduction in the number of cirrhosis complications
in the short term: −44% (10y). Nevertheless, both scenar-
ios S7 and S8 would require a similar number of treat-
ment courses over 10y; approximately 1,500, see Fig. 4.
These results show, that even in the context of new
DAAs, a large decrease in the disease burden using TasP,
first requires greater access to treatment for PWID once
they are diagnosed and linked to care. When this treat-
ment scale-up is achieved, improvements in other parts
of the cascade of care could result in additional benefits
for both HCV transmission and morbidity/mortality.
Without this treatment scale-up, increased testing or
linkage to care would be of limited benefit; these
patients would not initiate antiviral treatment before
several years, while experiencing ongoing fibrosis pro-
gression and continuing to be a source for new HCV
infections. Indeed, even if improvements in testing and
linkage to care are possible, testing and linkage to care
rates are already high relative to the treatment initiation
rate, with only 5%/year of PWID newly diagnosed and
linked to care initiating antiviral treatment. This repre-
sents a small number of individuals, and is reflected in
the number of people initiating treatment in scenarios 2
and 3 (Fig. 4).
This approach would be inconsistent with recent state-
ments from the European Association for the Study of
the Liver (EASL) [29] where screening of PWID is
promoted in part to improve access to treatment, but
also to reduce transmission. For the same reason, while
treatment initiation restricted to fibrosis scores ≥ F2
would reduce liver related morbidity, it would also delay
treatment for many other infected PWID. Indeed, in our
study, S7 (where treatment is initiated regardless of fi-
brosis level and at a rate of 20%/year) and S8 (where
treatment is initiated immediately for fibrosis ≥ F2 when
diagnosed and linked to care and without restricting
treatment number) required the same number of treat-
ments over the simulation period (see Fig. 4), however,
S7 had a greater impact on transmission. Delaying treat-
ment initiation until fibrosis scores ≥ F2 would effectively
allow for several years of ongoing HCV transmission be-
fore individuals reach treatment eligibility, and high
levels of sustained HCV incidence. This restriction may
be justified as it targets treatment to those most in need
in whom liver complications are more imminent. How-
ever, from a public health perspective, the treatment of
patients in the absence of liver disease (low fibrosis
scores) is most important to reduce HCV occurrence,
and consequently the disease burden over the long-term.
Modeling studies in other settings showed that even a
small increase in treatment availability for PWID can
result in a large decrease in HCV transmission in the
context of highly effective antivirals [30–32], particularly
in a low prevalence context [32]. However, these models
did not integrate the entire cascade of care, and thus did
not identify the specific steps in the cascade that have
the largest impact on the course of the HCV epidemic.
In Montréal, this appears to be treatment initiation once
PWID are diagnosed and linked to care.
In our sensitivity analysis, the mean time to cessation
of injection and the infection rate per infected injecting
partner had a strong impact on HCV incidence esti-
mates (see Additional file 1: S5). These results suggest
that improvements in primary and secondary prevention
interventions aimed at reducing the harms of substance
use (e.g., delayed initiation of injection drug use,
provision of clean injection equipment, opioid substitu-
tion therapies, and supervised injection facilities) would
complement a TasP strategy. A previous modeling study
in the United Kingdom demonstrated the importance of
combining risk reduction measures with a treatment
scale-up to achieve a high decrease in HCV prevalence
[33]. In our model, the current situation of risk reduc-
tion measures in Montréal was implicitly included in the
infection rate per infected partner values and the time to
cessation of injection; the heterogeneity with respect to
harm reduction uptake was neglected. Estimating the
impact of these preventive public health strategies, in
addition to variations in the HCV cascade of care, would
require a more complex model including information on
injecting drug use initiation, injection equipment
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distribution, use of opioid substitution therapies/pro-
grams, and supervised injection facilities, expected soon
in Montréal [34]. Further investigation is needed to
incorporate them in the model.
This study has several limitations. First, the network
model is static and relatively simple compared with
those for PWID in other countries using chain referral
sampling [19]. The paucity of data about the network
dynamic and topology constrained us, and the develop-
ment of a more realistic model would require field stud-
ies on PWID networks. Also, for simplicity, the model
did not explicitly include other comorbidities common
in PWID such as HIV infection [3]. We did not assume
a change in risk-taking among PWID after a positive
hepatitis C diagnosis. Some published studies show that
awareness of HCV infection is not associated with a de-
crease in risk-taking [35, 36]. While current recommen-
dations promote an individual-based treatment decision
for PWID [21, 22], treatment is probably preferentially
initiated in PWID with advanced levels of fibrosis. How-
ever, in our reference scenario, the treatment initiation is
independent of the fibrosis score. Finally, with the high
cost of the new DAAs (around 55,000$ Canadian for a
12-week course [25]), extended access to these antivirals
for the PWID population would mean increased costs
for the health system (see Fig. 4 for the number of com-
pleted treatment courses needed for each scenario).
Using projections based on the current number of pa-
tients treated, the cost of the introduction of the new
DAAs for the public health insurance system in Québec
is estimated to be 45 million Canadian dollars for the
first three years after introduction [24]. In addition, im-
proving testing or linkage to care would also be associ-
ated with costs. However, these high treatment costs
should be balanced against savings realized by averted
cirrhosis complications [37]. Future modeling works
could consider including health care costs to estimate
the costs of various strategies, including one involving
TasP.
Our study also has several strengths. The large amount
of local data available through ongoing regional surveil-
lance work (SurvUDI and the Notifiable Disease Report-
ing System of the Montréal Public Health Department)
and numerous past and current epidemiological studies
[8, 38–40] ensures the model reflects the current situ-
ation of HCV infection and care for PWID in Montréal.
Also, the model included the entire cascade of care for
chronic hepatitis C with testing, linkage to care and
treatment.
Conclusions
To conclude, TasP could lead to a large decrease in
chronic hepatitis C burden among PWID in Montréal.
The success of this strategy rests on first expanding ac-
cess to antiviral treatment to PWID already engaged in
HCV care. From a public health perspective, access to
antiviral treatment is a priority focus in improving the
HCV cascade of care. Limiting treatment to moderate to
severe fibrosis, while effective in circumventing cirrhosis
complications in the short-term, would do little to
curtail ongoing HCV transmission in this population.
Coupling greater treatment access with ongoing im-
provements in the HCV cascade of care would ultimately
result in less HCV occurrence and disease burden in
Montreal. Regardless, elimination of HCV infection (de-
fined as the reduction to zero of the incidence of infection
[15]) in this population would not be expected to occur in
the short to mid-term. Such an ambitious objective would
require a “TasP+” strategy, which would foster a commit-
ment to greater treatment access as well as harm reduction
Fig. 4 Cumulative number of treatments initiated in each scenario over 40 years of simulation
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services. Such a strategy would be in line with the
recent recommendations from the Québec Institute for
Excellence in Health and Social Services (INESSS): to
progressively lower (over several years) the fibrosis
threshold for access to combination sofosbuvir + ledi-
pasvir (highly effective, but costly) while also improving
harm reductions measures [41]. This would allow Que-
bec to be the first province in Canada where a true
TasP+ programmatic intervention could occur. In
future work, a more sophisticated model could help
evaluate the impact of a “TasP+” strategy; it would con-
sider ongoing improvements in the HCV cascade of
care while also determining the health care investment
needed to eliminate HCV infection among PWID.
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